{
  "drugs": [
    {
      "id": "levodopa",
      "name": "Levodopa (L-Dopa)",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease",
      "mechanism_of_action": "Dopamine precursor converted to dopamine in the CNS.",
      "target": "Dopamine deficiency replacement strategy",
      "sar_key_points": [
        "Catechol ring required for dopaminergic activity",
        "Amino acid scaffold allows transport across BBB via amino acid transporters",
        "Extensive peripheral metabolism limits CNS availability"
      ],
      "metabolism": "Decarboxylation and COMT-mediated O-methylation (dopamine pathway).",
      "pk_admet": "Short half-life; requires peripheral decarboxylase inhibitor to improve CNS delivery.",
      "ddis": [
        "Peripheral metabolism reduced by carbidopa coadministration"
      ],
      "clinical_significance": "Most effective therapy for motor symptoms of PD.",
      "checkpoints": [
        {
          "question": "Why must levodopa be combined with carbidopa?",
          "answer": "To block peripheral metabolism and increase CNS dopamine availability.",
          "hint": "Think peripheral decarboxylation."
        }
      ],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "carbidopa",
      "name": "Carbidopa",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease (Adjunct)",
      "mechanism_of_action": "Peripheral aromatic L-amino acid decarboxylase inhibitor.",
      "target": "DOPA decarboxylase (periphery)",
      "sar_key_points": [
        "Hydrazine functionality enables enzyme inhibition",
        "Does not cross BBB → selective peripheral action"
      ],
      "metabolism": "Forms hydrazone linkage with PLP cofactor of decarboxylase enzyme.",
      "pk_admet": "Improves levodopa bioavailability and reduces peripheral side effects.",
      "ddis": [],
      "clinical_significance": "Standard combination with levodopa therapy.",
      "checkpoints": [
        {
          "question": "Does carbidopa cross the BBB?",
          "answer": "No",
          "hint": "It is designed for peripheral selectivity."
        }
      ],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "rasagiline",
      "name": "Rasagiline",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease",
      "mechanism_of_action": "Irreversible MAO-B inhibitor → prevents dopamine breakdown.",
      "target": "Monoamine oxidase-B",
      "sar_key_points": [
        "Propargylamine group forms covalent interaction with MAO-B flavin cofactor",
        "Selectivity for MAO-B reduces tyramine dietary risk"
      ],
      "metabolism": "CYP1A2 metabolism → aminoindan metabolites.",
      "pk_admet": "Once-daily dosing; good CNS penetration.",
      "ddis": [
        "Avoid serotonergic combinations → serotonin syndrome risk"
      ],
      "clinical_significance": "Used as monotherapy or adjunct to levodopa.",
      "checkpoints": [
        {
          "question": "What functional group drives MAO-B irreversible inhibition?",
          "answer": "Propargylamine",
          "hint": "Covalent flavin binding."
        }
      ],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "selegiline",
      "name": "Selegiline",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease",
      "mechanism_of_action": "MAO-B inhibitor increasing CNS dopamine levels.",
      "target": "Monoamine oxidase-B",
      "sar_key_points": [
        "Propargylamine scaffold responsible for MAO-B inhibition",
        "Metabolized to amphetamine-like derivatives"
      ],
      "metabolism": "Produces N-desmethylselegiline and amphetamine metabolites.",
      "pk_admet": "Risk of stimulant-like adverse effects due to metabolites.",
      "ddis": [
        "Avoid serotonergic drugs → serotonin syndrome risk"
      ],
      "clinical_significance": "Adjunct therapy, less preferred due to metabolites.",
      "checkpoints": [],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "safinamide",
      "name": "Safinamide",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease",
      "mechanism_of_action": "Reversible MAO-B inhibitor with additional modulation effects.",
      "target": "Monoamine oxidase-B",
      "sar_key_points": [
        "Amide + aromatic ether scaffold",
        "Does not form amphetamine metabolites"
      ],
      "metabolism": "Amidase + CYP metabolism, glucuronidation pathways.",
      "pk_admet": "High bioavailability; adjunct in PD patients.",
      "ddis": [
        "Caution with serotonergic agents"
      ],
      "clinical_significance": "Adjunct option with improved tolerability.",
      "checkpoints": [],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "entacapone",
      "name": "Entacapone",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease (Adjunct)",
      "mechanism_of_action": "COMT inhibitor → prevents levodopa methylation in periphery.",
      "target": "Catechol-O-methyltransferase",
      "sar_key_points": [
        "Nitrocatechol pharmacophore essential for COMT binding",
        "Primarily peripheral action"
      ],
      "metabolism": "Glucuronidation major pathway (Z-isomerization).",
      "pk_admet": "Short acting; given with each levodopa dose.",
      "ddis": [],
      "clinical_significance": "Reduces wearing-off effect of levodopa.",
      "checkpoints": [],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "tolcapone",
      "name": "Tolcapone",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease (Adjunct)",
      "mechanism_of_action": "COMT inhibitor acting both centrally and peripherally.",
      "target": "Catechol-O-methyltransferase",
      "sar_key_points": [
        "Nitrocatechol scaffold binds COMT active site",
        "Greater potency than entacapone"
      ],
      "metabolism": "CYP3A4/CYP2D6 oxidation + glucuronidation.",
      "pk_admet": "Longer acting but hepatotoxicity risk.",
      "ddis": [],
      "clinical_significance": "Reserved due to liver toxicity concerns.",
      "checkpoints": [],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "apomorphine",
      "name": "Apomorphine",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease (Rescue)",
      "mechanism_of_action": "Dopamine receptor agonist (D2-like).",
      "target": "Dopamine receptors",
      "sar_key_points": [
        "Rigid polycyclic scaffold mimics dopamine binding conformation",
        "Catechol hydroxyl groups important for receptor interaction"
      ],
      "metabolism": "Extensive hepatic metabolism.",
      "pk_admet": "Rapid onset; used for acute off episodes.",
      "ddis": [],
      "clinical_significance": "Rescue therapy for sudden motor fluctuations.",
      "checkpoints": [],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "pramipexole",
      "name": "Pramipexole",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease",
      "mechanism_of_action": "Dopamine receptor agonist (D3-preferring).",
      "target": "Dopamine receptors",
      "sar_key_points": [
        "Non-catechol agonist improves stability",
        "Thiazole-containing scaffold"
      ],
      "metabolism": "Minimal hepatic metabolism.",
      "pk_admet": "Longer duration than levodopa.",
      "ddis": [],
      "clinical_significance": "Used early or adjunct in PD therapy.",
      "checkpoints": [],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "ropinirole",
      "name": "Ropinirole",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease",
      "mechanism_of_action": "Dopamine receptor agonist.",
      "target": "Dopamine receptors",
      "sar_key_points": [
        "Indole-based non-catechol scaffold"
      ],
      "metabolism": "CYP metabolism.",
      "pk_admet": "Oral agonist used in early PD.",
      "ddis": [],
      "clinical_significance": "Adjunct or monotherapy option.",
      "checkpoints": [],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    },
    {
      "id": "rotigotine",
      "name": "Rotigotine",
      "module": "PD",
      "therapeutic_area": "Parkinson’s Disease",
      "mechanism_of_action": "Dopamine receptor agonist delivered via transdermal patch.",
      "target": "Dopamine receptors",
      "sar_key_points": [
        "Thiophene-containing agonist scaffold",
        "Patch delivery improves adherence"
      ],
      "metabolism": "Hepatic metabolism.",
      "pk_admet": "Continuous delivery reduces fluctuations.",
      "ddis": [],
      "clinical_significance": "Transdermal dopamine agonist option.",
      "checkpoints": [],
      "admet_flags": [],
      "cyp_enzymes": [],
      "transporters": [],
      "half_life": "",
      "bioavailability": "",
      "bbb": "",
      "elimination": "",
      "contraindications": [],
      "boxed_warnings": [],
      "physchem": {
        "mw": "",
        "logp": "",
        "tpsa": "",
        "hbd": "",
        "hba": "",
        "pka": ""
      },
      "clinical_pearls": []
    }
  ]
}
